MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/700/0.01/20.09.24 | Market Closed - Börse Stuttgart 03:01:09 2024-07-16 pm EDT | ||
| 0.043 EUR | -2.27% |
|
| Current month | -4.44% | ||
| 1 month | -4.44% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 0.043 | -2.27% |
| 24-07-15 | 0.044 | -15.38% |
| 24-07-12 | 0.052 | +4.00% |
| 24-07-11 | 0.05 | -3.85% |
| 24-07-10 | 0.052 | +6.12% |
Delayed Quote Börse Stuttgart
Last update July 16, 2024 at 03:01 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | ME742W |
| ISIN | DE000ME742W2 |
| Date issued | 2024-01-18 |
| Strike | 700 $ |
| Maturity | 2024-09-20 (66 Days) |
| Parity | 100 : 1 |
| Emission price | 0.07 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.066 € |
|---|---|
| Lowest since issue | 0.032 € |
| Spread | 0.01 € |
| Spread % | 18.87% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
489
USD
Average target price
473.5
USD
Spread / Average Target
-3.17%
- Stock Market
- Warrants
- Warrant
